제일파마홀딩스

002620KOSPI회사 본부 및 경영 컨설팅 서비스업

49.5 / 100

Reference Date: 2026-06-10

Financial Score24.0 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but Revenue is on a declining trend. Plunged 17.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Jeil Pharma Holdings was formed through a corporate split in 2017, operating as a holding company overseeing investments, while its subsidiary Jeil Pharmaceuticals focuses on pharmaceutical manufacturing and sales. Key subsidiaries include Jeil Health Sciences (general pharmaceuticals) and Jeil & Partners (sales agency), with major products such as Lipito, Lyrica, and Kepentec. The company's core businesses include management consulting, leasing, investment income, and pharmaceutical sales.

Number of Employees

40people

Average Salary

73.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

3.30Industry Average 4.576.5Point

Lower than industry avg (good)

PBR

0.24Industry Average 0.314.0Point

In line with industry avg

ROE

7.64Industry Average 4.785.5Point

1.6x industry avg (good)

Debt Ratio

18.01Industry Average 29.295.0Point

Lower than industry avg (good)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼9.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲139.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -3.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 7,150Won52-week high 9,28052-week low 7,150

1-month return0.0Point

1m -17.34% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral[기재정정]분기보고서 (2026.03)2026-05-18
Neutral분기보고서 (2026.03)2026-05-15